Princeton vaccine reaches 90 percent of eligible

People walk at Princeton University in Princeton, N.J., Monday, Dec. 9, 2013. The Ivy League school has begun vaccinating nearly 6,000 students to try to stop an outbreak of type B meningitis in an unusual federal government-endorsed administration of a drug not generally approved for use in the United States. Seven students and one prospective student who was visiting campus have been stricken by potentially life-threatening type B meningococcal disease since March. None of the cases has been fatal. (AP Photo/Mel Evans)

Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Nearly 5,300 people chose to get the vaccine for the B strain of the meningitis bacteria. The vaccine is approved for use in Europe, Australia and Canada but is not yet approved for general use in the United States.

The U.S. Centers for Disease Control and Prevention recommended the unusual step and the Food and Drug Administration approved it.

The shots were available for all undergraduates along with some graduate students and employees Monday through Thursday.

Those who received the vaccine are recommended to get booster doses in February.

Related Stories

Precautions urged against meningitis

date Dec 06, 2013

Recent outbreaks of meningitis at Princeton University and other college campuses across the nation have students on alert, but there are ways to lessen the threat, says Madhuri Sopirala, MD, associate professor of infectious ...

Recommended for you

AAPM: Platelet-rich plasma offers short-term benefit

date 1 hour ago

(HealthDay)—For patients with facet joint arthropathy, platelet-rich plasma (PRP) has a short-term positive impact, according to a study presented at the annual meeting of the American Academy of Pain Medicine, ...

Brittle bone disease: Drug research offers hope

date 5 hours ago

New research at the University of Michigan offers evidence that a drug being developed to treat osteoporosis may also be useful for treating osteogenesis imperfecta or brittle bone disease, a rare but potentially debilitating ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.